Moderna (NASDAQ: MRNA) shares are trading higher on Thursday amid growing concerns of U.S. coronavirus cases. Dr. Anthony Fauci earlier said the company will likely be going into advanced Phase 3 trials by the end of July.
Moderna is engaged in creating transformative medicines based on messenger RNA, or mRNA. It transfers the information stored in the genes to the cellular machinery that makes all the proteins required for life. The firm is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases.
Moderna shares were trading up 5.17% at $64.76 at the time of publication on Thursday. The stock has a 52-week high of $87 and a 52-week low of $11.54.
Moderna Strikes Another Coronavirus Vaccine Manufacturing Deal To Ensure Overseas Supply
See more from Benzinga
- Strategist Expects Gold, Silver To Gain As Pandemic Panic Subsides
- Why Moderna's Stock Is Trading Higher Today
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.